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Abstract
Introduction: Duration of risk symptoms (DUR) in people at clinical high risk for psychosis (CHR-P) has been related
to poorer clinical outcomes, such as reduced functioning, but it is currently unclear how different symptoms
emerge as well as their link with cognitive deficits. To address these questions, we examined the duration of basic
symptoms (BS) and attenuated psychotic symptoms (APS) in a sample of CHR-P participants to test the hypothesis
that BS precede the manifestation of APS. As a secondary objective, we investigated the relationship between DUR,
functioning and neuropsychological deficits.
Methods: Data from 134 CHR-P participants were assessed with the Comprehensive Assessment of At-Risk Mental
State and the Schizophrenia Proneness Interview, Adult Version. Global, role and social functioning and
neurocognition were assessed and compared to a sample of healthy controls (n = 57).
Results: In CHR-P participants who reported both APS and BS, onset of BS and APS was not significantly related.
When divided into short and long BS duration (</> 8 years), CHR-P participants with a longer duration of BS
showed evidence for an onset of BS preceding APS (n = 8, p = 0.003). However, in the short BS duration group, APS
showed evidence of preceding BS (n = 56, p = 0.020). Finally, there were no significant effects of DUR on cognition
or functioning measures.
Conclusion: The present findings do not support the view that APS constitute a secondary phenomenon to BS.
Moreover, our data could also not confirm that DUR has a significant effect on functioning and cognitive deficits.
These findings are discussed in the context of current theories regarding emerging psychosis and the importance
of DUR.
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Introduction
An important assumption of research on the duration of
untreated illness (DUI) in psychosis is the hypothesis of
a critical period during which, when left untreated,
psychotic symptoms lead to poorer clinical outcomes
[1]. Studies have so far primarily focused on the duration
of untreated psychosis (DUP), i.e., the time between the
first occurrence of frank positive psychotic symptoms
and the diagnosis of psychosis or initiation of an anti-
psychotic treatment [1]. DUP is an important concept
that has stimulated research in relation to functional and
symptomatic outcomes [2], and, as a result, supported
the case for early intervention in individuals experien-
cing first episode psychosis (FEP) [3]. Research on DUI
in the psychosis prodrome yielded similar findings, indi-
cating that longer duration of untreated prodromal
symptoms in FEP-patients was associated with lower
general functioning [4], and increased negative symp-
toms [5].
More recently, several studies have examined the rela-
tionship between the duration of risk symptoms (DUR)
in participants that meet clinical high-risk for psychosis
(CHR-P) criteria. Emerging evidence has highlighted that
subthreshold symptoms in CHR-P participants may con-
fer a similar relationship with clinical and functional
outcomes as in FEP [6]. Specifically, studies in CHR-P
participants that meet Ultra High-Risk (UHR) criteria
have examined the question of whether longer DUR
increases the likelihood for transition to psychosis, but
findings have been inconclusive [7–9]. In addition, pre-
liminary evidence from clinical samples indicate that
poorer global functioning is related to increased DUR [6,
9, 10]. Thus, lower functioning has been linked to longer
duration of UHR symptoms [6, 9] as well as attenuated
negative symptoms [7]. One study examined the effect
of duration of attenuated psychotic symptoms (APS)
symptoms on cognition [11] but no effect was demon-
strated. Finally, there is currently only one study that has
examined of duration of basic symptoms (BS) on func-
tioning [10] while the link with cognition has not been
investigated.
CHR-P participants are defined by meeting UHR and/
or BS criteria [12, 13]. UHR criteria are defined by the
presence of APS as well as by the presence of brief lim-
ited intermittent psychotic symptoms (BLIPS), or by a
genetic risk of a psychotic disorder and a significant de-
crease in mental state or functioning, occurring within
the preceding 12 months [12]. In contrast, BS-criteria in-
volve self-experienced cognitive and perceptual
anomalies that are hypothesized to detect potential
psychosis risk during the early stage of development
[14]. Importantly, the co-occurrence of APS and BS has
been related to higher transition rates to psychosis [15,
16] (but see [17] for different findings). Moreover, the
combination of APS and BS has been linked to pro-
nounced functional impairments and elevated psycho-
pathology in CHR-P participants [17, 18].
Models of emerging psychosis have suggested that
APS and BLIPS are preceded by BS [14, 19]. BS are
assumed to represent the most immediate symptomatic
expression of the neurobiological correlates of schizo-
phrenia [19, 20], while APS have been considered to
result from poor or inadequate coping with emerging BS
[19]. Currently, there is only limited evidence for this
temporal relationship . Schultze-Lutter et al. [21] exam-
ined the duration of BS and APS in a FEP sample. Only
a third of FEP-patients reported an onset of BS before
APS, while another third was characterized by the simul-
taneous emergence of APS and BS. The remaining par-
ticipants were characterized by an earlier manifestation
of APS compared to BS [21]. Education mediated the re-
lationship between BS and APS onset [21] as well as age
of onset and sex [19].
The present study attempted to clarify the relationship
between the duration of BS and APS in a sample of
CHR-P participants by comparing DUR obtained in rou-
tine clinical ratings. Based on previous theoretical evi-
dence [19, 21, 22], we hypothesized that in the majority
of CHR-P participants, BS would precede the manifest-
ation of APS. In addition, we investigated the role of
DUR on functioning and cognition, given the import-
ance of DUP for clinical outcomes in FEP-patients and
emerging evidence for a similar relationship between
DUR and functioning in CHR-P participants [6, 7, 9, 11].
Specifically, we hypothesized that longer DUR would im-
pact on functioning as well as cognition.
Methods
Recruitment and participants
The data were collected as part of the Youth Mental
Health Risk and Resilience (YouR) study [23], a longitu-
dinal study to identify the psychological and neurobio-
logical mechanisms and predictors of psychosis-risk. The
YouR-study was approved by the NHS Research Ethical
Committee Glasgow and Greater Clyde, and is funded
by the Medical Research Council. The majority of the
CHR-P participants were recruited from the community
through on online detection approach as described
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previously [24]. Participants provided written informed
consent.
To establish CHR-P criteria, the Comprehensive As-
sessment of At Risk Mental States (CAARMS) [12]
and the Schizophrenia Proneness Instrument, Adult
version (SPI-A) [13] were used. Interviews were ad-
ministered by trained research assistants, MSc and
PhD level-researchers. Inter-rater reliability (IRR) of
CHR-P status as determined by the CAARMS and
SPI-A ratings was good to excellent (CAARMS:
92.0%; SPI-A: 95.7%). CAARMS criteria for CHR-P
were as follows: 1) APS group (subthreshold psychotic
syndrome present in the last year) 2) BLIPS and 3)
Genetic risk and functional decline (GRFD). SPI-A
criteria included COPER and COGDIS. CHR-P partic-
ipants were excluded for current or past diagnosis of
an axis-I psychotic disorder.
In addition, a control group (n = 60, 42 female, 18
male) was recruited without an axis I diagnosis or family
history of psychotic disorders. Potential participants
were screened with the Mini-International Neuropsychi-
atric Interview (MINI [25]). and completed the demo-
graphic, functional and neurocognitive measures.
Assessment of DUR
Duration of APS and BS was obtained from CAARMS
and SPI-A assessments. CAARMS items from the posi-
tive scale were considered if a) a frequency score of 3–5
and b) an intensity rating of ≥3 on the unusual thought
content or non-bizarre ideas, or perceptual abnormal-
ities scale or ≥ 4 on the disorganised speech scale was
met [12]. BS items were included when symptoms had a
frequency rating of > 3. APS and BS with symptom dur-
ation since early childhood and no change in symptom
severity were excluded as these are considered more
equivalent to schizotypal traits.
Only DUR-scores for which the participant was able to
identify the month of onset, the year of onset (treated as
January 1st of that year), or age when the symptom
emerged, were included for analysis. DUR was deter-
mined by the number of months from symptom onset –
irrespective of the initial frequency of occurrence – until
the date of the baseline interview, in line with previous
studies [6–9, 11, 21].
Clinical and cognitive assessments
In addition to the CAARMS and SPI-A interviews, all
participants were administered the M.I.N.I [25]. Func-
tioning was assessed with the global assessment of func-
tioning (GAF) and the social and role scales (GF: social
and role) [26] at baseline. In addition, the Brief Assess-
ment of Cognition in Schizophrenia Battery (BACS)
[27]) as well as the following tasks from the University
of Pennsylvania Computerized Neuropsychological
Testing Battery (PennCNP [28]): a) Continuous Per-
formance Test b) the N-Back Task, and c) Emotion
Identification Task, were administered.
Statistical analysis
All statistical analysis were performed using R [29].
Criteria-relevant CAARMS and SPI-A symptoms with
the longest reported duration for each participant were
entered into the analysis. For individuals who reported
both APS and BS symptoms, the symptom with the lon-
gest duration was entered into the analysis.
Group differences in clinical and demographic mea-
sures were calculated using Pearson’s Chi-squared test,
Bartlett’s test of homogeneity of variances, Kruskal-
Wallis rank sum test, and one-way ANOVA tests. To as-
sess the relationship between onset of BS and APS, dur-
ation of APS and BS were separately recorded and z-
scored using the means and standard deviations in the
CHR-P group. Paired t-tests and robust linear regression
was used to evaluate the relationship between APS and
BS. Secondary analyses were conducted by dividing
CHR-P participants with short vs. long duration of BS
[22] which were defined as </> 1 SD from the mean.
Cohen’s d was calculated to measure effect sizes.
For analysis of APS/BS duration and functioning mea-
sures, quantile regressions were used to examine the re-
lationship with DUR, as GAF scores and social and role
functioning failed to meet the assumptions of parametric
measures. In addition, neurocognitive data was
converted into standardized z-scores for each cognitive
domain by using the means and standard deviations of
the control group in line with previous studies [6, 9].
Linear regression was used to examine the relationship
between DUR and cognition.
Results
Demographic and cognitive data
The CHR-P participants differed from controls in age at
baseline and years of education. Specifically, the CHR-P
group had poorer functioning in global, role and social
measures (Table 1).
For 26 CHR-P participants, no cognitive data was
available. For the remaining CHR-Ps, there were signifi-
cant impairments compared to controls in working
memory, executive function, attention accuracy and in
the BACS composite score. In addition, CHR-P partici-
pants were characterized by slower reaction times in the
emotion recognition task (Table 2).
CHR-P with APS & BS vs. APS or BS alone
Of the CHR-P participants screened, 77.57% of those
with APS reported duration of symptoms (n = 109), and
68.67% of those with BS reported duration data (n = 89).
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A total of 134 CHR-P reported APS or BS duration
(87.58%).
The average duration for APS was 43months and for
BS was 51 months (Table 3), but individual symptoms
showed significantly different duration (Fig. 1). CHR-P
participants reporting both APS/BS showed a general
trend towards longer DUR, compared to those with only
APS or BS, but this finding was not significant.
Relationship between APS and BS onset
Of the CHR-P participants who met both APS/BS-cri-
teria (n = 64), n = 31 (48.4%) reported an onset of BS
prior to APS onset, while n = 24 (37.5%) reported
APS onset prior to BS. Nine (14.1%) CHR-P partici-
pants reported APS and BS onset occurring in the
same month. No significant difference in duration
was found for BS onset preceding APS (paired t-test:
t = 0.02, df = 63, p = 1.0). Robust linear regression ana-
lysis which accounted for outliers also failed to find a
relationship between BS and APS onset (robust re-
gression: B = − 0.065, SE = 0.129, t-value = − 0.502, F-
test =0.252, p = 0.616).
Secondary analyses examining the relationship be-
tween short or long BS duration (defined as >/< 1
SD (≈ 8 years)) and onset of APS were conducted to
examine potential group differences. Short BS dur-
ation showed a significant relationship (paired t-test:
t = − 2.40, df = 55, p = 0.020, MD = − 0.3, 95%CI [−
0.54, − 0.05]; effect size d = − 0.17), indicating that
APS preceded BS onset. Robust linear regression
failed to find a significant relationship (robust re-
gression: B = 0.227, SE = 0.149, t-value = 1.52, F = 2.27,
p = 0.138). An opposite pattern was observed, how-
ever, for the long BS duration group, with BS
Table 1 Demographic, functional and clinical characteristics of CHR-P and Controls
Controls CHR-P df H/χ2 p
Number of participants 60 134
Female participants, n (%) 42 (68.9) 93 (69.4) 1 χ2 = 0.00 1.0
Age at baseline, median (range) 22 (18–32) 20 (16–34) 1 H = 6 0.01
Age at onset, median (range) – 17 (4–31)
Years in education, median (range) 16 (12–24) 15 (8–26) 1 H = 127 <0.001
UK citizen, N (%) 28 (45.9) 97 (72.4) 1 χ2 = 12 <0.001
GAF, median (range) 88 (67–97) 58 (21–95) 1 H = 32 <0.001
GF: Role, median (range) 9 (5–9) 8 (4–9) 1 H = 55 <0.001
GF: Social, median (range) 9 (7–9) 8 (5–9) 1 H = 67 <0.001
Current medication, n (%)
No medication 60 (98.36) 68 (50.75) 1 χ2 = 42 <0.001
Anti-psychotic 0 2 (01.49) 1 χ2 = 0.01 0.9
Mood stabiliser 0 1 (0.75) 1 χ2 = 0.00 1.0
Anti-depressant 0 30 (22.39) 1 χ2 = 15 <0.001
Anti-convulsant 0 1 (0.75) 1 χ2 = 0.00 1.0
Other 1 (1.64) 13 (9.70) 1 χ2 = 3 0.06
Multiple 0 21 (15.67) 1 χ2 = 8 0.005
Lifetime diagnosis, n (%)
No diagnosis 57 (95.0) 21 (15.67) 1 χ2 = 126 <0.001
Anxiety disorder 2 (3.33) 89 (66.42) 1 χ2 = 77 <0.001
Mood disorders 0 86 (64.18) 1 χ2 = 73 <0.001
Eating disorders 0 13 (9.70) 1 χ2 = 5 0.03
Alcohol dependence/abuse 1 (1.67) 40 (29.85) 1 χ2 = 18 <0.001
Substance dependence/abuse 0 21 (15.67) 1 χ2 = 10 0.001
Suicidality n (%)
Suicidality 1 (1.67) 72 (53.73) 1 χ2 = 49 <0.001
No diagnosis 59 (98.33) 62 (46.27)
Abbreviations: CHR-P clinical high risk for psychosis, df degrees of freedom, H Kruskal-Wallis H test, χ2 Chi-Squared test, GAF Global Assessment of Functioning,
GF:Role/Social Global Functioning Role & Social Scale
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occurring prior to APS onset (paired t-test: t = 4,
df = 7, p = 0.003, MD = 2.1, 95% CI [0.96–3.24]),
which persisted when outliers were accounted for
(robust regression: B =− 1.318, SE = 0.441, t-value = − 2.988,
F = 8.819, p= 0.025; effect size d = − 2.8).
Paired t-tests were conducted to determine
between-group differences of BS onset compared to
APS onset. Education (individuals with/without third
level education), age of onset (>/< 18 years of age at
onset of either symptom type), and gender were sep-
arately analysed. No significant effects were observed
that mediated the pattern of onset between BS and
APS (Supplemental Table 1).
Relationship between DUR and functioning
19 CHR-P participants did not complete assessments
for functional measures and were excluded from the
analysis. Duration of APS and BS showed no signifi-
cant effects on GAF scores, role functioning or social
functioning in any of the CHR-P groups (Table 4).
Relationship between DUR and cognition
Longer APS duration was associated with impaired
verbal fluency but this effect did not survive corrections
for multiple comparisons (p = 0.22). No additional
cognitive subtest correlated with APS or BS duration
(Table 5).
Discussion
The current study examined BS and APS in a CHR-P
sample to test current models of emerging psychosis as
well as the effects of DUR on functioning and cognitive
deficits. The main finding is that we could not confirm
the hypothesis that BS preceded the development of
APS. Moreover, we could not replicate findings indicat-
ing that longer DUR was related to poor functioning [6,
9, 10], but our findings are consistent with previous evi-
dence suggesting that cognitive deficits were not influ-
enced by DUR [11].
DUR in the current CHR-P sample that was largely
community-recruited was longer than in previous CHR-
P samples obtained from clinical pathways [6–8, 11].
Accordingly, one possibility is that longer DUR may be
the result of the absence of an early intervention service
in our catchment area and thus we detected CHR-P par-
ticipants at a later stage of illness. While the impact of
recruitment strategies on the clinical characteristics of
CHR-P probands continues to be discussed [30, 31], it is
important to note that the CHR-P participants in the
current study were characterized by similar neuro-
psychological and global functioning scores as those re-
ported for clinically-referred CHR-P cohorts [32].
An important finding is that criteria-relevant BS did
not precede APS in the majority of CHR-P participants.
In fact, APS onset preceded BS in a considerable portion
of the sample (37.5%, n = 24). In addition, there was no
significant evidence between duration of BS and APS.





df F (95%) CI p Cohen’s d
M SD M SD
BACS
Verbal memory 0 1 −0.23 1.22 56 1 0.92, 2.23 0.10 −0.2
Working memory 0 1 − 0.07 1.26 56 2 0.99, 2.41 0.053 − 0.06
Motor speed 0 1 −0.79 1.12 56 1 0.78, 1.89 0.401 −0.73
Attention & processing speed 0 1 −0.49 1.16 56 1 0.84, 2.05 0.20 −0.44
Verbal fluency 0 1 −0.14 0.62 56 0.8 0.49, 1.19 0.20 −0.29
Executive function 0 1 −0.04 1.36 56 2 1.1, 2.8 0.011 −0.03
BACS composite score 0 1 −0.64 1.51 56 2 1.4, 3.4 <0.001 −0.46
Penn CNB
Emotion recognition accuracy 0 1 −0.16 1.00 56 1 0.62, 1.50 0.900 −0.15
Emotion recognition RT 0 1 0.43 1.28 56 2 1.0, 2.5 0.030 0.36
Working memory accuracy 0 1 −0.29 1.15 56 2 1.1, 2.8 0.010 −0.3
Working memory RT 0 1 −0.09 0.80 56 0.7 0.41, 1.00 0.049 −0.1
Attention accuracy 0 1 −0.37 1.29 56 2 1.0, 2.5 0.041 −0.3
Attention RT 0 1 −0.13 0.88 56 1 0.6 1.5 0.80 −0.18
Abbreviations: M Mean, SD Standard deviation, df degrees of freedom, F F-statistic, CI Confidence intervals, p p-value, RT Reaction time
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Table 3 Demographic and Clinical Characteristics of CHR-P Subgroups
APS & BS APS BS df K2/H/χ2 p
Number of participants 64 45 25
Female participants, n (%) 44 (68.8) 34 (75.6) 15 (60.0) 2 χ2 = 2 0.4
Age at baseline, median (range) 21 (16–34) 19 (16–32) 21 (17–31) 2 H = 4 0.1
Age at onset, median (range) 17 (5–29) 18 (4–31) 17 (5–25) 2 H = 2 0.3
Years in education, median (range) 15 (10–26) 14 (8–21) 15 (11–18) 2 H = 6 0.04
UK citizen, N (%) 46 (71.9) 31 (68.9) 20 (80.0) 2 χ2 = 0.8 0.7
ARMS
APS criteria, n = 109 (81.34%) 64 45 – 1 χ2 = 0.00 1.0
BLIPS criteria 0 0 –
Severity score, mean (range) 16.31 (1–30) 15.31 (9–25) – 1 K2 = 0.36 0.549
COPER
Criteria, n = 88 (61.94%) a 61 – 27 χ2 = 1.17 0.280
Sum score, mean (range) 4.07 (3–6) – 4.05 (3–6) K2 = 2.85 0.092
COGDIS
Criteria, n = 57 (32.09%)a 39 – 18 χ2 = 0.70 0.403
Sum score, mean (range) 4.35 (3–6) – 4.13 (3–6) K2 = 0.18 0.669
Mean duration (SD), in months
APS 46 (45) 39 (54) – F = 0.54 0.46
BS 54 (45) – 48 (43) F = 0.38 0.54
Median duration (range), in months
APS 37 (1–226) 12 (2–246) – H = 3 0.08
BS 44 (1–180) – 37 (3–187) H = 0.6 0.4
GAF, median (range) 55 (21–95) 57 (21–86) 62 (34–95) H = 3 0.2
GF: Role, median (range) 8 (4–9) 8 (4–9) 8 (6–9) H = 2 0.4
GF: Social, median (range) 8 (5–9) 8 (5–9) 8 (6–10) H = 0.8 0.7
Current medication, n (%)
No medication 28 (43.8) 23 (51.1) 12 (48.0) 2 χ2 = 0.5 0.8
Anti-psychotic 1 (1.6) 1 (2.2) 0 2 χ2 = 0.5 0.8
Mood stabiliser 0 0 1 (4.0) 2 χ2 = 4 0.1
Anti-depressant 16 (25.0) 11 (24.4) 3 (12.0) 2 χ2 = 2 0.4
Anti-convulsant 0 0 1 (4.0) 2 χ2 = 4 0.1
Other 9 (14.1) 3 (6.7) 3 (12.0) 2 χ2 = 2 0.5
Multiple 9 (14.1) 7 (15.6) 5 (20.0) 2 χ2 = 0.4 0.8
Lifetime diagnosis, n (%)
No diagnosis 5 (7.8) 3 (6.7) 4 (16.0) 2 χ2 = 2 0.3
Anxiety disorder 45 (70.3) 32 (71.1) 12 (48.0) 2 χ2 = 3 0.2
Mood disorders 57 (89.1) 27 (60.0) 12 (48.0) χ2 = 4 0.1
Eating disorders 6 (9.4) 6 (13.3) 1 (4.0) χ2 = 1 0.5
Alcohol dependence/abuse 20 (31.3) 14 (31.1) 6 (24.0) χ2 = 0.2 0.9
Substance dependence/abuse 7 (10.9) 11 (24.4) 3 (12.0) χ2 = 4 0.2
Suicidality n (%)
Suicidality 35 (20.0) 24 (45.8) 13 (23.1) χ2 = 0.1 0.9
a = note 37 participants met both COGDIS & COPER criteria. Abbreviations: X2 Pearson’s Chi-squared test, K2 Bartlett test of homogeneity of variances, H Kruskal-
Wallis rank sum test, F one way ANOVA, ARMS at-risk mental state, APS attenuated psychotic symptoms, BLIPS brief limited intermittent psychotic symptoms, BS
Basic symptoms, COPER Cognitive-perceptive basic symptoms, COGDIS Cognitive disturbances basic symptoms
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Moreover, in the short BS duration group (< 1 SD ≈ 8
years), APS also preceded BS onset. Only in the small
long BS duration group (n = 8) was there evidence of BS
duration being significantly longer than APS.
Analyses for between group differences based on sex,
age at onset, and years of education also failed to find
evidence of BS preceding APS onset. This finding differs
from data reported in a FEP-cohort, which linked the se-
quence of BS onset preceding APS to higher school edu-
cation, male gender and an onset of mental health issues
before age 18 [21, 22].
Moreover, in contrast to previous studies [6, 9, 10], we
found no significant effect of APS or BS duration on
GAF scores, role or social functioning (but see [7]). One
possibility is that community recruited CHR-P partici-
pants may reflect different trajectories for the develop-
ment of psychosis than those who are identified through
clinical pathways, which may be characterized by a more
insidious onset, for example.
Confirming our previous findings [32], CHR-P partici-
pants were characterized by moderate impairments in
cognition, in particular in regards to working memory,
attention and executive processes. In line with Chon and
colleagues [11], there was only marginal evidence for a
Fig. 1 Median duration of first onset APS and/or BS Disturbances of abstract thinking (O3) was not reported by any participant as a first onset
basic symptom, so excluded from the figure. Abbreviations: APS attenuated psychotic symptom, BS basic symptom, Decreased ability to
discriminate … Decreased ability to discriminate between ideas/perception and fantasy/true memories, Captivation of attention … Captivation of
attention by details of the visual field
Table 4 Effect of Duration of CHR-P Symptoms on Functional
Measures
B SE t 95% CI p
APS (n = 45)
GAF − 0.033 0.030 −1.11 − 0.06, 0.05 0.272
GF: Role 0.000 0.004 0.00 −0.00, 0.01 1.00
GF: Social 0.000 0.003 0.00 −0.01, 0.01 1.00
BS (n = 25)
GAF −0.16 0.13 −1.22 − 0.38, 0.01 0.241
GF: Role −0.006 0.005 −1.28 − 0.01, 0.01 0.215
GF: Social −0.006 0.010 − 0.60 − 0.02, 0.03 0.557
APS & BS (n = 64)
GAF 0.035 0.041 0.87 −0.06, 0.09 0.389
GF: Role −0.005 0.004 −1.15 −0.01, 0.00 0.256
GF: Social 0.00 0.004 0.00 −0.01, 0.01 1.00
Abbreviations: B unstandardized estimate, SE Standard error, t t-value, CI
Confidence intervals, p p-value
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Table 5 Association of Duration of CHR-P Symptoms on Cognition
B SE t 95% CI R2 p
APS (n = 45)
BACS
Verbal memory 0.001 0.004 0.30 −0.01, 0.01 0.002 0.767
Working memory 0.002 0.004 0.57 −0.00, 0.01 0.009 0.571
Motor speed −0.002 0.004 −0.68 − 0.01, 0.01 0.038 0.503
Processing speed −0.001 0.003 −0.16 − 0.01, 0.01 0.001 0.876
Verbal fluency −0.003 0.001 −2.4 −0.01, 0.00 0.13 0.022
Executive function 0.006 0.004 1.25 −0.00, 0.01 0.040 0.218
BACS composite score 0.002 0.005 0.47 −0.01, 0.01 0.006 0.643
Penn CNP
Emotion recognition accuracy 0.003 0.003 1.13 −0.00, 0.01 0.033 0.267
Emotion recognition RT 0.003 0.003 0.86 −0.00, 0.01 0.020 0.396
Attention accuracy 0.004 0.004 0.82 −0.01, 0.01 0.018 0.416
Attention RT − 0.004 0.002 −1.5 − 0.01, 0.01 0.057 0.143
Working memory accuracy 0.001 0.004 0.22 −0.01, 0.01 0.001 0.826
Working memory RT 0.001 0.002 0.31 −0.00, 0.01 0.003 0.755
BS (n = 25)
BACS
Verbal memory 0.008 0.006 1.17 −0.01, 0.02 0.071 0.256
Working memory 0.009 0.007 1.30 −0.01, 0.03 0.086 0.211
Motor speed −0.01 0.006 −0.90 −0.02, 0.01 0.804 0.382
Processing speed 0.003 0.007 0.39 −0.01, 0.02 0.008 0.701
Verbal fluency 0.004 0.004 0.99 −0.01, 0.01 0.051 0.338
Executive function −0.001 0.008 −0.07 −0.02, 0.02 0.000 0.938
BACS composite score 0.006 0.010 0.68 −0.01, 0.03 0.025 0.506
Penn CNP
Emotion recognition accuracy 0.005 0.006 0.93 −0.01, 0.02 0.046 0.366
Emotion recognition RT −0.002 0.008 −0.24 −0.02, 0.01 0.003 0.815
Attention accuracy 0.003 0.007 0.35 −0.01, 0.02 0.007 0.730
Attention RT −0.006 0.005 −1.0 −0.02, 0.01 0.056 0.317
Working memory accuracy −0.001 0.007 −0.12 −0.02, 0.01 0.001 0.902
Working memory RT −0.004 0.005 −0.87 −0.01, 0.01 0.040 0.396
APS & BS (n = 64)
BACS
Verbal memory −0.002 0.003 −0.64 −0.01, 0.00 0.007 0.523
Working memory 0.001 0.003 0.38 −0.01, 0.01 0.003 0.703
Motor speed −0.002 0.003 −0.65 −0.01, 0.00 0.007 0.519
Processing speed −0.002 0.003 −0.76 −0.01, 0.00 0.010 0.452
Verbal fluency 0.000 0.002 0.18 −0.00, 0.00 0.001 0.856
Executive function −0.006 0.003 −1.95 −0.01, 0.00 0.063 0.056
BACS composite score −0.004 0.003 −1.23 −0.01, 0.01 0.026 0.244
Penn CNP
Emotion recognition accuracy −0.003 0.002 −1.02 −0.01, 0.00 0.018 0.313
Emotion recognition RT 0.000 0.003 0.01 −0.01, 0.01 0.000 0.996
Staines et al. BMC Psychiatry          (2021) 21:339 Page 8 of 11
relationship between DUR and cognitive performance in
CHR-P participants, however. This finding is also con-
sistent with data in FEP-patients [33], highlighting that
DUP does not have an impact on cognitive deficits dur-
ing early-stage psychosis.
Finally, several studies [15, 16, 18] have indicated
that CHR-P participants with a combination of APS
and BS had a higher risk of transition to psychosis as
well as more severe psychopathology and lower func-
tioning [16, 17], raising the possibility that this sub-
group of CHR-P participants may also be
characterized by differences in DUR. Again, we could
not confirm this hypothesis, although a moderate
trend was observable for a longer DUR in CHR-P in-
dividuals with both APS and BS. Similarly, function-
ing was also not significantly lower in those with APS
and BS compared to those with only APS or BS, in
contrast to previous evidence [18].
Limitations
There are several limitations to the current findings.
Firstly, as in previous studies, DUR relied on retrospect-
ive self-reports, which are potentially vulnerable to both
recognition and recall bias [21, 22]. Moreover, the over-
all sample size as well as the number of participants who
reported both APS and BS symptoms were modest, yet
similar to previous findings [21]. The current sample
was primarily collected from a community sample and
previous studies have found differences in symptom se-
verity and functioning scores between community and
help-seeking CHR-P participants [34] as well as lower
transition rates [31].
Conclusions
There is currently only limited evidence on the dur-
ation of CHR-P symptoms, the relationship between
BS and APS, and their relationship to functional out-
comes and cognition. One key finding of this paper is
that APS does not emerge as a secondary conse-
quence of BS. Indeed, in the short BS duration group,
evidence showed APS preceded BS. Importantly, the
current findings also highlight that community-
recruited CHR-P participants experienced substantially
longer duration of subthreshold symptoms compared
to previous studies. However, we could not confirm
that DUR had a significant effect on functioning or
cognition. This raises the question whether DUR is
an important variable for the understanding of emer-
ging psychosis in CHR-P participants or a suitable
potential target for early intervention.
To address these question, further studies in larger
CHR-P samples need to be conducted that utilize more
sophisticated assessment of DUR, including development
of specific tools and guidelines. This might offer greater
clarity into the potential link between DUR on clinical
and functional outcomes in CHR-P participants and for
measures to reduce DUR in emerging psychosis.
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